Working… Menu

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02262741
Recruitment Status : Completed
First Posted : October 13, 2014
Last Update Posted : October 23, 2017
Information provided by (Responsible Party):
MedImmune LLC

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 21, 2017
Actual Study Completion Date : September 21, 2017